Vanguard Group Inc. Has $39.99 Million Stock Position in RxSight, Inc. (NASDAQ:RXST)

Vanguard Group Inc. lifted its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 21.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,433,953 shares of the company's stock after buying an additional 255,150 shares during the period. Vanguard Group Inc. owned approximately 4.00% of RxSight worth $39,993,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in RXST. BluePath Capital Management LLC purchased a new position in shares of RxSight during the 3rd quarter worth approximately $32,000. Lazard Asset Management LLC purchased a new position in RxSight in the second quarter worth $70,000. Tower Research Capital LLC TRC lifted its holdings in RxSight by 788.0% in the third quarter. Tower Research Capital LLC TRC now owns 3,046 shares of the company's stock valued at $85,000 after acquiring an additional 2,703 shares during the period. IFP Advisors Inc purchased a new stake in shares of RxSight during the 2nd quarter worth $112,000. Finally, UBS Group AG grew its stake in shares of RxSight by 413.6% during the 4th quarter. UBS Group AG now owns 5,388 shares of the company's stock worth $68,000 after purchasing an additional 4,339 shares during the period. 78.78% of the stock is owned by institutional investors and hedge funds.

RxSight Stock Up 4.9 %

Shares of NASDAQ RXST traded up $2.59 on Thursday, hitting $55.31. The company had a trading volume of 206,905 shares, compared to its average volume of 446,636. The firm has a market capitalization of $2.05 billion, a P/E ratio of -38.68 and a beta of 1.22. The business has a 50 day moving average of $51.91 and a two-hundred day moving average of $39.72. RxSight, Inc. has a 12-month low of $17.00 and a 12-month high of $58.21.

RxSight (NASDAQ:RXST - Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.10. The business had revenue of $28.58 million for the quarter, compared to analyst estimates of $28.60 million. RxSight had a negative return on equity of 31.16% and a negative net margin of 54.57%. On average, sell-side analysts anticipate that RxSight, Inc. will post -0.94 earnings per share for the current year.

Insider Activity at RxSight

In other RxSight news, Director William J. Phd Link sold 28,250 shares of the firm's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $49.67, for a total transaction of $1,403,177.50. Following the completion of the transaction, the director now directly owns 24,248 shares of the company's stock, valued at approximately $1,204,398.16. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other RxSight news, Director William J. Phd Link sold 28,250 shares of the company's stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $49.67, for a total transaction of $1,403,177.50. Following the sale, the director now owns 24,248 shares in the company, valued at $1,204,398.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Shweta Maniar sold 6,399 shares of the stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $45.72, for a total value of $292,562.28. Following the transaction, the director now directly owns 12,130 shares in the company, valued at approximately $554,583.60. The disclosure for this sale can be found here. Insiders have sold 148,040 shares of company stock valued at $7,280,585 over the last ninety days. Corporate insiders own 21.13% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on RXST. Stifel Nicolaus increased their target price on shares of RxSight from $54.00 to $64.00 and gave the company a "buy" rating in a report on Thursday, February 29th. Wells Fargo & Company upgraded RxSight from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $31.00 to $42.00 in a report on Wednesday, December 13th. Needham & Company LLC reiterated a "buy" rating and set a $64.00 price objective on shares of RxSight in a report on Thursday. Oppenheimer lifted their price target on shares of RxSight from $54.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, February 29th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of RxSight from $40.00 to $62.00 and gave the company an "overweight" rating in a research note on Thursday, February 29th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, RxSight has a consensus rating of "Buy" and a consensus target price of $49.63.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.